THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results